Heparin-induced thrombocytopenia in surgical patients

American Journal of Surgery

Volumn 199, Issue 1, 2010, Pages 43-51

  Battistelli, Sandra ^a   Genovese, Alberto ^a   Gori, Tommaso ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Anticoagulants; Fondaparinux; Heparin; Heparin induced thrombocytopenia; Low molecular weight heparin; Platelets

Indexed keywords

ARGATROBAN; DANAPAROID; FONDAPARINUX; HIRULOG; LEPIRUDIN; ANTIVITAMIN K; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANAPHYLAXIS; BLEEDING; CLINICAL FEATURE; DIAGNOSTIC TEST; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MONITORING; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INCIDENCE; PATHOGENESIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SURGICAL PATIENT; THROMBOCYTOPENIA; THROMBOSIS; AWARENESS; DRUG WITHDRAWAL; RISK FACTOR; SYSTEMATIC REVIEW;

ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INCIDENCE; MALE; POSTOPERATIVE COMPLICATIONS; RISK ASSESSMENT; SURGICAL PROCEDURES, OPERATIVE; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 72049108898     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2009.01.029     Document Type: Review

References (62)

1. Warkentin T.E. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 121 (2003) 535-555
2. Greinacher A., and Warkentin T.E. Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update. Thromb Res 118 (2006) 165-176
3. Warkentin T.E. Heparin-induced thrombocytopenia. Disorders 51 (2005) 141-149
4. Warkentin T.E. An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost 30 (2004) 273-283
5. Arepally G.M., and Ortel T.L. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 355 (2006) 809-817
6. Rauova L., Poncz M., McKenzie S.E., et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 105 (2005) 131-138
7. Greinacher A., Farner B., Kroll H., et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 94 (2005) 132-135
8. Lee D.H., and Warkentin T.E. Frequency of heparin-induced thrombocytopenia. In: Warkentin T.E., and Greinacher A. (Eds). Heparin-Induced Thrombocytopenia. 4th edn. (2007), Informa Healthcare, USA, Inc, New York 67-116
9. Warkentin T.E., and Kelton J.G. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344 (2001) 1286-1292
10. Warkentin T.E., and Kelton J.G. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 135 (2001) 502-506
11. Martel N., Lee J., and Wells P.S. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106 (2005 Oct. 15) 2710-2715
12. Warkentin T.E., Sheppard J.A., Sigouin C.S., et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 108 (2006) 2937-2941
13. McNulty I., Katz E., and Kim K.Y. Thrombocytopenia following heparin flush. Prog Cardiovasc Nurs 20 (2005) 143-147
14. Warkentin T.E., Roberts R.S., Hirsh J., et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 163 (2003) 2518-2524
15. Warkentin T.E., Sheppard J.A., Horsewood P., et al. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96 (2000) 1703-1708
16. Klenner A.F., Lubenow N., Raschke R., et al. Heparin-induced thrombocytopenia in children: 12 new cases and review of the literature. Thromb Haemost 91 (2004) 719-724
17. Matsuo T., Tomaru T., Kario K., et al. Incidence of heparin-PF4 complex antibody formation and heparin-induced thrombocytopenia in acute coronary syndrome. Thromb Res 115 (2005) 475-481
18. Warkentin T.E., Greinacher A., Koster A., and Lincoff A.M. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133 (2008) 340-380
19. Guyatt G.H., Cook D.J., Jaeschke R., et al. Grades of recommendation for antithrombotic agents. Chest 133 (2008) 123S-131S
20. Chilver-Stainer L., Lämmle B., and Alberio L. Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems. Thromb Haemost 91 (2004) 276-282
21. Bennett-Guerrero E., Slaughter T.F., White W.D., et al. Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg 130 (2005) 1567-1572
22. Calaitges J.G., Liem T.K., Spadone D., et al. The role of heparin-associated antiplatelet antibodies in the outcome of arterial reconstruction. J Vasc Surg 29 (1999) 779-785
23. Greinacher A., Eichler P., Lietz T., et al. Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia. Blood 106 (2005) 2921-2922
24. Hirsh J., Heddle N., and Kelton J.G. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 164 (2004 Febr. 23) 361-369
25. Hong A.P., Cook D.J., Sigouin C.S., et al. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 101 (2003) 3049-3051
26. Lewis B.E., Wallis D.E., Hursting M.J., et al. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 129 (2006) 1407-1416
27. Fabris F., Luzzatto G., Soini B., et al. Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia. J Intern Med 252 (2002) 149-154
28. Opatrny L., and Warner M.N. Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia. Am J Hematol 76 (2004) 240-244
29. Warkentin T.E., and Kelton J.G.A. 14-year study of heparin-induced thrombocytopenia. Am J Med 101 (1996) 502-507
30. Workentin T.E. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin T.E., and Greinacher A. (Eds). Heparin-Induced Thrombocytopenia. 4th edn. (2007), Informa Healthcare, USA, Inc, New York 21-66
31. Warkentin T.E. Heparin-induced skin lesions. Br J Haematol 92 (1996) 494-497
32. Warkentin T.E. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 127 suppl (2005) 35S-45S
33. Lewis B.E., Wallis D.E., Berkowitz S.D., et al., ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103 (2001) 1838-1843
34. Lubenow N., Eichler P., Lietz T., et al. Lepirudin in patients with heparin-induced thrombocytopenia-results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 3 (2005) 2428-2436
35. Lo G.K., Juhl D., Warkentin T.E., et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4 (2006) 759-765
36. Walenga J.M., Jeske W.P., Fasanella A.R., et al. Laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost 25 suppl 1 (1999) 43-49
37. Walenga J.M., Jeske W.P., Fasanella A.R., et al. Laboratory diagnosis of heparin-induced thrombocytopenia. Clin Appl Thromb/Hemost 5 suppl 1 (1999) S21-S27
38. Warkentin T.E., and Sheppard J.A. Testing for heparin-induced thrombocytopenia antibodies. Transfus Med Rev 20 (2006) 259-272
39. Greinacher A., Janssens U., Berg G., et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-associated thrombocytopenia study (HAT) investigators. Circulation 100 (1999) 587-593
40. Greinacher A., Völpel H., Janssens U., et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 99 (1999) 73-80
41. Tardy B., Lecompte T., Boelhen F., et al., GEHT-HIT Study Group. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood 108 (2006) 1492-1496
42. Greinacher A., Lubenow N., and Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 108 (2003) 2062-2065
43. Eichler P., Friesen H.J., Lubenow N., et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on APTT, and clinical relevance. Blood 96 (2000) 2373-2378
44. Lewis B.E., Wallis D.E., Leya F., et al., Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 163 (2003) 1849-1856
45. Mahaffey K.W., Lewis B.E., Wildermann N.M., et al., ATBAT Investigators. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol 15 (2003) 611-616
46. Stone G.W., McLaurin B.T., Cox D.A., et al., ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355 (2006) 2203-2216
47. Magnani H.N., and Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 95 (2006) 967-981
48. Chong B.H., Gallus A.S., Cade J.F., et al., Australian HIT Study Group. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study. Thromb Haemost 86 (2001) 1170-1175
49. Farner B., Eichler P., Kroll H., et al. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 85 (2001) 950-957
50. Walenga J.M., Jeske W.P., Bara L., et al. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 86 (1997) 1-36
51. Petitou M., Duchaussoy P., Jaurand G., et al. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide. (SR 90,107A/orig 31,540). J Med Chem 40 (1997) 1600-1607
52. Warkentin T.E., Cook R.J., Marder V.J., et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 106 (2005) 3791-3796
53. Amiral J., Lormeau J.C., Marfaing-Koka A., et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 8 (1997) 114-117
54. Ahmad S., Jeske W.P., Walenga J.M., et al. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin Appl Thromb/Hemost 5 (1999) 259-266
55. Harenberg J., Jörg I., and Fenyvesi T. Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica 89 (2004) 1017-1018
56. Bradner J., Hallisey R.K., and Kuter D.J. Fondaparinux in the treatment of heparin-induced thrombocytopenia. (abstract). Blood 104 (2004) 1775
57. Lobo B., Finch C., Howard A., et al. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 99 (2008) 208-214
58. Kovacs M.J. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost 93 (2005) 999-1000
59. Stratmann G., deSilva A.M., Tseng E.E., et al. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg 98 (2004 Jun) 1635-1639
60. Bijsterveld N.R., Moons A.H., Boekholdt S.M., et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 106 (2002) 2550-2554
61. Yee A.J., and Kuter D.J. Successful recovery from an overdose of argatroban. Ann Pharmacother 40 (2006) 446-449
62. Rice L. Heparin-induced thrombocytopenia: myths and misconceptions (that will cause trouble for you and your patient). Arch Intern Med 164 (2004) 1961-1964